Sarepta Therapeutics Reports Strong Financial Performance and Advances in Gene and RNA Therapies for Rare Diseases in 2025
Sarepta Therapeutics, Inc., a recognized leader in precision genetic medicine for rare diseases, today reported its financial results for the fourth quarter and full-year 2025, alongside significant clinical and corporate milestones. The company’s performance last year underscores its continued commitment to innovation in genetic medicine and its dedication to patients and families affected by rare diseases.
Doug Ingram, Chief Executive Officer of Sarepta Therapeutics, emphasized that the company entered 2026 from a position of strength despite the challenges of 2025. “Following a tumultuous 2025, we entered 2026 from a position of strength, founded on: (a) solid financial footing with a robust and growing cash balance, substantial revenue, and no near-term debt overhang, (b) durable approved therapies that are bringing a better life to patients, with significant yet-tapped opportunity for ELEVIDYS gene therapy, and (c) an exciting, potentially best-in-class siRNA pipeline of advancing therapies for DM1, FSHD, Huntington’s disease, idiopathic pulmonary fibrosis, SCA1, SCA2 and SCA3,” he stated.
Ingram further highlighted the company’s strategic achievements over the past year: “In 2025, we streamlined our operations, delivered strong revenue, and ended the year with nearly $1.0 billion in cash—as we anticipate remaining profitable and cash‑flow positive in 2026. ELEVIDYS has emerged from a challenging year with a clear label, traditional approval for ambulatory patients, and a plan intended to put us on a potential pathway back to serving the non‑ambulatory community. We are executing comprehensive plans designed to arm treating physicians and families with accurate and balanced information to unlock the full potential of this transformative and needed therapy. At the same time, our PMO exon-skipping therapies continue to demonstrate durable clinical value, exceptional safety, extraordinary real-world outcomes, and unwavering support from families and physicians. Finally, with five clinical-stage RNAi programs and multiple readouts ahead, we are poised for meaningful growth while advancing therapies that can profoundly change the lives of patients living with rare disease.”
Financial Highlights and Strategic Positioning
Sarepta ended 2025 with a strong financial foundation, highlighted by nearly $1 billion in cash reserves and no near-term debt overhang. The company also refinanced $291.4 million of its 2027 convertible notes in December 2025 by exchanging them for new 2030 convertible notes along with $31.6 million in cash. This transaction left $158.6 million of the original notes outstanding and significantly reduced potential debt pressures, positioning Sarepta for long-term financial stability.
The company anticipates remaining profitable and cash-flow positive throughout 2026, leveraging its growing portfolio of approved therapies and its robust pipeline of investigational genetic and RNA-based treatments.
ELEVIDYS Gene Therapy: Transformative Progress and Global Expansion
ELEVIDYS (delandistrogene moxeparvovec-rokl), Sarepta’s first and only approved gene therapy for Duchenne muscular dystrophy (DMD), continued to demonstrate meaningful clinical benefits and global expansion in 2025 and early 2026.
In February 2026, Chugai Pharmaceutical Co. launched ELEVIDYS Intravenous Infusion in Japan, marking the country’s first regenerative medical product for Duchenne muscular dystrophy. The launch follows approval by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in May 2025. In Japan, ELEVIDYS is approved for the treatment of Duchenne in children aged 3 to less than 8 years old, who do not have deletions in exon 8 or exon 9 of the DMD gene and are negative for anti-AAVrh74 antibodies. Sarepta is eligible to receive a $40 million milestone payment upon the first commercial sale in Japan, further underscoring the company’s potential for revenue growth from international markets.
In addition to geographic expansion, Sarepta reported positive three-year results from Part 1 of the EMBARK study (Study SRP‑9001‑301), a global, randomized, Phase 3 trial evaluating ELEVIDYS. The results indicate that three years after treatment, patients who received ELEVIDYS maintained motor function above their baseline North Star Ambulatory Assessment (NSAA) scores, whereas matched external controls experienced the expected age-related decline. The therapy produced clinically meaningful, statistically significant, and durable benefits across all key functional endpoints, including NSAA, Time to Rise (TTR), and 10-meter walk/run (10MWR). Patients treated with ELEVIDYS demonstrated a 73% slowing of disease progression in TTR and 70% in 10MWR relative to the external control group at Year 3, with the performance gap widening between Years 2 and 3.
Safety data from the EMBARK study remained consistent with prior observations, showing no new treatment-related safety signals over the three-year follow-up. These findings reinforce ELEVIDYS’ potential to modify the trajectory of Duchenne muscular dystrophy by preserving muscle function over time, offering hope to patients and families seeking long-term improvements in mobility and quality of life.
The U.S. Food and Drug Administration (FDA) approved updated prescribing information for ELEVIDYS in November 2025, including a boxed warning for serious liver injury, removal of the non-ambulatory indication, and expanded guidance on immunosuppression, monitoring, and corticosteroid use. The company also received approval to initiate Cohort 8 of the ENDEAVOR study (Study 9001-103), which evaluates an enhanced immunosuppressive regimen in non-ambulant individuals with Duchenne, further expanding the potential patient population that can benefit from ELEVIDYS.
Exon-Skipping Therapies: Durable Outcomes and Real-World Evidence
Sarepta’s PMO exon-skipping therapies continued to demonstrate exceptional clinical value in 2025. These therapies remain well-tolerated with strong efficacy, supported by extraordinary real-world outcomes. Families and physicians consistently report high levels of satisfaction and continued support, highlighting the ongoing importance of these therapies in managing Duchenne muscular dystrophy.
In 2026, Sarepta plans to present new long-term and safety data across its gene therapy and exon-skipping programs at the Muscular Dystrophy Association Clinical & Scientific Conference. These presentations will include caregiver-reported outcomes, reinforcing the durable efficacy of dystrophin restoration in slowing disease progression and supporting informed treatment decisions.
RNAi Therapeutics Pipeline: Advancing Precision Medicine
Sarepta’s investigational small interfering RNA (siRNA) therapies remain a key focus, targeting a range of rare genetic diseases. In January 2026, the company received approval to initiate a first-in-human Phase 1 clinical trial of SRP‑1005, an siRNA therapeutic for Huntington’s disease, assessing safety and tolerability in approximately 24 participants starting in Q2 2026.
Additionally, the Phase 1/2 multiple ascending dose (MAD) study of SRP-1003 (formerly ARO-DM1) for myotonic dystrophy type 1 (DM1) continues to progress. Cohorts 1 (1.5 mg/kg) and 2 (3 mg/kg) are complete, and cohort 3 (4.5 mg/kg) is fully enrolled and ongoing. Following a positive pre-specified drug safety committee review, the study is expected to advance with additional drug-escalating cohorts.
Beyond DM1 and Huntington’s disease, Sarepta is actively developing RNAi therapies for facioscapulohumeral muscular dystrophy (FSHD), idiopathic pulmonary fibrosis, and spinocerebellar ataxias (SCA1, SCA2, SCA3). The company’s RNAi platform is designed to deliver precision genetic medicine, offering hope for transformative disease-modifying therapies across multiple rare diseases.
Advancing Early Detection and Patient Access
Sarepta’s commitment to improving patient outcomes extends beyond therapy development to early disease detection. Duchenne muscular dystrophy was recently added to the U.S. Recommended Uniform Screening Panel (RUSP), marking a significant milestone for the Duchenne community. Inclusion in the RUSP encourages broader newborn screening at the state level, empowering families with early diagnosis and timely information to pursue early care and access available therapies, including clinical trials. Each state administers its own newborn screening program and relies on federal evidence-based recommendations, such as the RUSP, to guide which conditions to add to their panels.
